Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Summary

This phase I trial studies the side effects and best dose of talazoparib in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have spread to other places in the body (metastatic) and cannot be removed by surgery and liver or kidney dysfunction. Talazoparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

• Estrogen Receptor Negative
• Head and Neck Squamous Cell Carcinoma
• HER2/Neu Negative
• Hormone-Resistant Prostate Cancer
• Metastatic Pancreatic Adenocarcinoma
• Progesterone Receptor Negative
• Solid Neoplasm
• Stage III Mesothelioma
• Stage IIIA Gastric Cancer
• Stage IIIA Non-Small Cell Lung Cancer
• Stage IIIA Ovarian Cancer
• Stage IIIA Small Cell Lung Carcinoma
• Stage IIIB Gastric Cancer
• Stage IIIB Non-Small Cell Lung Cancer
• Stage IIIB Ovarian Cancer
• Stage IIIB Small Cell Lung Carcinoma
• Stage IIIC Gastric Cancer
• Stage IIIC Ovarian Cancer
• Stage IV Mesothelioma
• Stage IV Non-Small Cell Lung Cancer
• Stage IV Ovarian Cancer
• Stage IV Small Cell Lung Carcinoma
• Triple-Negative Breast Carcinoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Talazoparib

Given PO

Sponsors & Collaborators

• National Cancer Institute (NCI)

  lead NIH

Principal Investigators

• Daniel Renouf · University Health Network Princess Margaret Cancer Center LAO

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-06-30

Primary Completion

2018-10-31